Memo Therapeutics

Memo Therapeutics AG ("MTx"), an Ipsen company, is a late-stage biotechnology company headquartered at Wagistrasse 27 in Schlieren / Zurich, Switzerland, with a US office as Memo Therapeutics US, Inc. in Wilson, North Carolina. It develops best-in-class therapeutic antibodies to transform the lives of patients with viral infections and cancer, built on DROPZYLLA, a microfluidic single-cell platform that makes a recombinant in vitro copy of an individual donor's B-cell antibody repertoire, banks it as a library, and screens it functionally at high throughput. Its lead program, potravitug, is a first-in-class monoclonal antibody against BK polyomavirus (BKPyV) reactivation in kidney transplant recipients; the Phase II SAFE KIDNEY II trial reported biopsy-proven resolution of BKPyV-associated nephropathy with sustained viral-load reduction to week 38, and the asset holds EU orphan designation. In February 2026 the company entered a collaboration and option agreement with CSL for its recombinant polyclonal IgG technology carrying milestones of up to CHF 265 million, and it has run an oncology antibody-discovery collaboration with Ono Pharmaceutical since 2022 alongside nephrology collaborations with the University Hospital of Zurich and the University Hospital of Bern. Ipsen completed its acquisition of Memo Therapeutics AG on 22 July 2026, adding potravitug to Ipsen's rare-disease pipeline. Memo Therapeutics runs no developer program and publishes no product API, developer portal, SDK or API documentation. The only machine-readable surface reachable without credentials is the WordPress REST content API behind memo-therapeutics.com, catalogued here, together with an llms.txt the site's SEO plugin publishes.

Memo Therapeutics is listed with 1 API on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Antibody Therapeutics, and Rare Disease.

Memo Therapeutics’ developer surface includes product news, authentication, and 25 more developer resources.

🌐 Visit website 📡 Source on GitHub

18.6/100 emerging ▬ flat Agent 10/100 agent aware Front door AI 1/6 silent saas Full breakdown ↓
scored 2026-10-09 · rubric v0.23.0

1 API

Company Biotechnology Pharmaceuticals Antibody Therapeutics Rare Disease NephrologytransplantationvirologyOncology Clinical Trials Life Sciences Switzerland content-api

Kin Score

Kin Score How this is scored →
scored 2026-10-09 · rubric v0.23.0

Composite quality — 18.6/100 · emerging

Contract Quality 0.0 / 21

Developer Ergonomics 3.9 / 17

Access Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Contract Governance 1.9 / 10

Discoverability 5.5 / 9

Regulatory Posture 2.9 / 15

Agent readiness — 10/100 · agent aware

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 6 / 6

MCP Server 0 / 12

Machine-Readable Auth 10 / 10

Idempotency 9 / 9

Stable Error Semantics 8 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 7 / 7

Typed Event Surface 0 / 6

Agent Skills 5 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 4 / 4

Delegated User Identity 0 / 6

Protected Resource Metadata 0 / 5

Registration Without a Human 0 / 6

Agentic Commerce Well-Known Document 0 / 5

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

Create-or-Update Ergonomics does not apply to this provider. The published contracts declare no write operations, and a read-only API cannot create-or-update. The facet is excluded from this provider's denominator entirely — not scored zero. A reference or data API is not deficient for being unable to upsert.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/memo-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

APIs 1

Individual APIs this provider publishes, each with its own machine-readable definition.

Memo Therapeutics Website (WordPress REST)

The public WordPress REST API (wp-json) of the Memo Therapeutics website at memo-therapeutics.com: the route index of the site's content management system, catalogued as one sit...

Pricing Plans 1

Published pricing tiers and plan structures.

Memo Therapeutics Plans Pricing

0 plans

PLANS

Rate Limits 1

Documented rate limits and quota policies.

Memo Therapeutics Rate Limits

0 limits

RATE LIMITS

OpenAPI Overlays 1

Overlays applied on top of this provider's contracts. Each card says who wrote it: a document the provider publishes, or one API Evangelist derived or generated.

Memo Therapeutics Content Overlay

5 actions · update

GENERATED

Security Posture 2

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Memo Therapeutics Authentication

3 schemes

SECURITY

Memo Therapeutics Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

AgentSkill

AgentSkill

Design & Contract 5

Pagination, idempotency, versioning, errors, and events

Conventions

Conformance

ErrorCatalog

Lifecycle

DataModel

Access & Security 2

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Authentication

Authentication

Operate 2

Status, limits, changes, and where to get help

Contact

Contact

RateLimits

RateLimits

Commercial 3

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Plans

Plans

Company 6

The organization behind the API

Website

About

News

BlogRSS

Careers

LinkedIn

Other 7

Properties that don't map to a standard resource type

CookiePolicy

PatientResources

Disclaimer

Science

ParentCompany

Sitemap

Overlay

Scroll for all 7

Source (apis.yml)

aid: memo-therapeutics
name: Memo Therapeutics
description: Memo Therapeutics AG ("MTx"), an Ipsen company, is a late-stage biotechnology company headquartered at Wagistrasse
  27 in Schlieren / Zurich, Switzerland, with a US office as Memo Therapeutics US, Inc. in Wilson, North Carolina. It develops
  best-in-class therapeutic antibodies to transform the lives of patients with viral infections and cancer, built on DROPZYLLA,
  a microfluidic single-cell platform that makes a recombinant in vitro copy of an individual donor's B-cell antibody repertoire,
  banks it as a library, and screens it functionally at high throughput. Its lead program, potravitug, is a first-in-class
  monoclonal antibody against BK polyomavirus (BKPyV) reactivation in kidney transplant recipients; the Phase II SAFE KIDNEY
  II trial reported biopsy-proven resolution of BKPyV-associated nephropathy with sustained viral-load reduction to week 38,
  and the asset holds EU orphan designation. In February 2026 the company entered a collaboration and option agreement with
  CSL for its recombinant polyclonal IgG technology carrying milestones of up to CHF 265 million, and it has run an oncology
  antibody-discovery collaboration with Ono Pharmaceutical since 2022 alongside nephrology collaborations with the University
  Hospital of Zurich and the University Hospital of Bern. Ipsen completed its acquisition of Memo Therapeutics AG on 22 July
  2026, adding potravitug to Ipsen's rare-disease pipeline. Memo Therapeutics runs no developer program and publishes no product
  API, developer portal, SDK or API documentation. The only machine-readable surface reachable without credentials is the
  WordPress REST content API behind memo-therapeutics.com, catalogued here, together with an llms.txt the site's SEO plugin
  publishes.
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: true
  label: Hosted service · you call their endpoint
  confidence: high
  source:
  - openapi
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - authentication
  - rate-limits
  - security
  generated: '2026-09-03'
  method: derived
image: https://memo-therapeutics.com/wp-content/uploads/2024/07/memo-therapeutics-ipsen-logo.webp
url: https://raw.githubusercontent.com/api-evangelist/memo-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.23'
created: '2026-08-25'
modified: '2026-08-25'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Antibody Therapeutics
- Rare Disease
- Nephrology
- transplantation
- virology
- Oncology
- Clinical Trials
- Life Sciences
- Switzerland
- content-api
tags_raw:
- Company
- biotechnology
- pharmaceuticals
- antibody-therapeutics
- rare-disease
- nephrology
- transplantation
- virology
- oncology
- clinical-trials
- life-sciences
- switzerland
- content-api
apis:
- aid: memo-therapeutics:memo-therapeutics-com-website-wordpress-rest
  name: Memo Therapeutics Website (WordPress REST)
  description: 'The public WordPress REST API (wp-json) of the Memo Therapeutics website at memo-therapeutics.com: the route
    index of the site''s content management system, catalogued as one site surface rather than as separate APIs.'
  baseURL: https://memo-therapeutics.com/wp-json
  tags:
  - WordPress
  x-surface: platform-generated
  properties:
  - type: Documentation
    url: https://memo-therapeutics.com/wp-json
  x-platform: wordpress
  x-platform-surface: rest
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/memo-therapeutics-domain-security.yml
- type: Website
  url: https://memo-therapeutics.com/
- type: About
  url: https://memo-therapeutics.com/about-us/
- type: News
  url: https://memo-therapeutics.com/latest-news/
- type: BlogRSS
  url: https://memo-therapeutics.com/feed/
- type: Contact
  url: https://memo-therapeutics.com/contact-us/
- type: PrivacyPolicy
  url: https://memo-therapeutics.com/privacy-policy/
- type: TermsOfService
  url: https://memo-therapeutics.com/terms-and-conditions/
- type: CookiePolicy
  url: https://memo-therapeutics.com/cookie-policy/
- type: PatientResources
  url: https://memo-therapeutics.com/expanded-access-policy/
- type: Disclaimer
  url: https://memo-therapeutics.com/further-information/
- type: Science
  url: https://memo-therapeutics.com/bkv/
- type: Careers
  url: https://www.ipsen.com/careers/
- type: LinkedIn
  url: https://www.linkedin.com/company/memo-therapeutics-ag/
- type: ParentCompany
  url: https://www.ipsen.com/
- type: Sitemap
  url: https://memo-therapeutics.com/sitemap.xml
- type: Authentication
  url: authentication/memo-therapeutics-authentication.yml
- type: Conventions
  url: conventions/memo-therapeutics-conventions.yml
- type: Conformance
  url: conformance/memo-therapeutics-conformance.yml
- type: ErrorCatalog
  url: errors/memo-therapeutics-problem-types.yml
- type: Lifecycle
  url: lifecycle/memo-therapeutics-lifecycle.yml
- type: DataModel
  url: data-model/memo-therapeutics-data-model.yml
- type: RateLimits
  url: rate-limits/memo-therapeutics-rate-limits.yml
- type: Plans
  url: plans/memo-therapeutics-plans-pricing.yml
- type: Overlay
  url: overlays/memo-therapeutics-content-overlay.yaml
- type: LLMsTxt
  url: llms/memo-therapeutics-llms.txt
- type: AgentSkill
  url: skills/_index.yml
x-enrichment:
  date: '2026-08-25'
  status: enriched
  artifacts_added: 26
  pass: local-v1

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools →

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/memo-therapeutics"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/memo-therapeutics/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/memo-therapeutics/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no form to fill in. Signing in shares your email address with us — we store it to create your key and to recognise you if you sign in with another provider. See our Privacy Policy and Terms.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.